Sartorius Stedim Biotech S.A. (SDMHF)
USD 201.5
(0.0%)
USD 201.5
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.23 Billion EUR | -32.76% |
| 2022 | 1.83 Billion EUR | 18.13% |
| 2021 | 1.55 Billion EUR | 54.88% |
| 2020 | 1 Billion EUR | 33.99% |
| 2019 | 748.34 Million EUR | 18.87% |
| 2018 | 629.56 Million EUR | 13.47% |
| 2017 | 554.82 Million EUR | 5.32% |
| 2016 | 526.82 Million EUR | 16.61% |
| 2015 | 451.78 Million EUR | 32.24% |
| 2014 | 341.65 Million EUR | 16.55% |
| 2013 | 293.12 Million EUR | 6.78% |
| 2012 | 274.5 Million EUR | 15.14% |
| 2011 | 238.42 Million EUR | 10.56% |
| 2010 | 215.65 Million EUR | 13.31% |
| 2009 | 190.33 Million EUR | 8.26% |
| 2008 | 175.8 Million EUR | 47.24% |
| 2007 | 119.4 Million EUR | -51.4% |
| 2006 | 245.67 Million EUR | 8.47% |
| 2005 | 226.48 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 306.3 Million EUR | -0.68% |
| 2024 Q1 | 308.4 Million EUR | 21.8% |
| 2024 Q3 | 275.4 Million EUR | -10.09% |
| 2023 Q4 | 253.2 Million EUR | -9.86% |
| 2023 Q3 | 280.9 Million EUR | -13.54% |
| 2023 Q2 | 324.9 Million EUR | -13.24% |
| 2023 Q1 | 374.5 Million EUR | -20.84% |
| 2023 FY | 1.23 Billion EUR | -32.76% |
| 2022 FY | 1.83 Billion EUR | 18.13% |
| 2022 Q4 | 473.1 Million EUR | 2.62% |
| 2022 Q1 | 454.5 Million EUR | 11.59% |
| 2022 Q3 | 461 Million EUR | 3.39% |
| 2022 Q2 | 445.9 Million EUR | -1.89% |
| 2021 Q1 | 351.8 Million EUR | 30.38% |
| 2021 Q2 | 384.3 Million EUR | 9.24% |
| 2021 Q3 | 409.9 Million EUR | 6.66% |
| 2021 Q4 | 407.3 Million EUR | -0.63% |
| 2021 FY | 1.55 Billion EUR | 54.88% |
| 2020 Q4 | 269.83 Million EUR | -2.24% |
| 2020 Q3 | 276 Million EUR | 17.65% |
| 2020 Q2 | 234.6 Million EUR | 5.34% |
| 2020 Q1 | 222.7 Million EUR | 16.69% |
| 2020 FY | 1 Billion EUR | 33.99% |
| 2019 Q3 | 191.6 Million EUR | 1.59% |
| 2019 Q4 | 190.84 Million EUR | -0.39% |
| 2019 FY | 748.34 Million EUR | 18.87% |
| 2019 Q2 | 188.6 Million EUR | 6.37% |
| 2019 Q1 | 177.3 Million EUR | 11.96% |
| 2018 Q2 | 159.1 Million EUR | 8.01% |
| 2018 Q1 | 147.3 Million EUR | 1.85% |
| 2018 FY | 629.56 Million EUR | 13.47% |
| 2018 Q4 | 158.36 Million EUR | -3.96% |
| 2018 Q3 | 164.9 Million EUR | 3.65% |
| 2017 Q2 | 139.1 Million EUR | 1.31% |
| 2017 FY | 554.82 Million EUR | 5.32% |
| 2017 Q4 | 144.62 Million EUR | 7.77% |
| 2017 Q3 | 134.2 Million EUR | -3.52% |
| 2017 Q1 | 137.3 Million EUR | 6.42% |
| 2016 Q1 | 125.5 Million EUR | 16.76% |
| 2016 Q4 | 129.02 Million EUR | -8.5% |
| 2016 FY | 526.82 Million EUR | 16.61% |
| 2016 Q3 | 141 Million EUR | 7.39% |
| 2016 Q2 | 131.3 Million EUR | 4.62% |
| 2015 Q4 | 107.48 Million EUR | -14.83% |
| 2015 Q1 | 102.8 Million EUR | 16.02% |
| 2015 Q2 | 115.3 Million EUR | 12.16% |
| 2015 FY | 451.78 Million EUR | 32.24% |
| 2015 Q3 | 126.2 Million EUR | 9.45% |
| 2014 Q4 | 88.6 Million EUR | 4.0% |
| 2014 Q2 | 85.5 Million EUR | 9.76% |
| 2014 Q3 | 85.2 Million EUR | -0.35% |
| 2014 FY | 341.65 Million EUR | 16.55% |
| 2014 Q1 | 77.9 Million EUR | 8.46% |
| 2013 Q2 | 80.9 Million EUR | 0.0% |
| 2013 Q4 | 71.82 Million EUR | 0.31% |
| 2013 Q3 | 71.6 Million EUR | -11.5% |
| 2013 FY | 293.12 Million EUR | 6.78% |
| 2012 FY | 274.5 Million EUR | 15.14% |
| 2012 Q2 | 69.4 Million EUR | 0.0% |
| 2011 Q2 | 60.2 Million EUR | 0.0% |
| 2011 FY | 238.42 Million EUR | 10.56% |
| 2010 FY | 215.65 Million EUR | 13.31% |
| 2010 Q2 | 54.7 Million EUR | 0.0% |
| 2009 FY | 190.33 Million EUR | 8.26% |
| 2008 FY | 175.8 Million EUR | 47.24% |
| 2007 FY | 119.4 Million EUR | -51.4% |
| 2006 FY | 245.67 Million EUR | 8.47% |
| 2005 FY | 226.48 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| American Medical Technologies Inc. | 1.69 Million USD | -72496.958% |
| Ansell Limited | 624.8 Million USD | -97.423% |
| Ansell Limited | 624.8 Million USD | -97.423% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 113.94 Million USD | -982.569% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | 135.05 Thousand USD | -913231.606% |
| Psykey, Inc. | 415.97 Thousand USD | -296431.531% |
| ConvaTec Group Plc | 1.2 Billion USD | -2.526% |
| ConvaTec Group Plc | 1.17 Billion USD | -4.997% |
| Encision Inc. | 3.13 Million USD | -39234.023% |
| Golden Valley Development, Inc | - USD | -Infinity% |
| Hear AtLast Holdings, Inc. | - USD | -Infinity% |
| Innovative MedTech Inc. | 794.01 Thousand USD | -155250.101% |
| LifePoint, Inc. | -71.35 Thousand USD | 1728707.865% |
| Medite Cancer Diagnostics, Inc. | -131 Thousand USD | 941703.053% |
| Paradigm Medical Industries, Inc. | 525 Thousand USD | -234852.381% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | 603.24 Thousand USD | -204379.146% |
| Reflect Scientific, Inc. | 596.42 Thousand USD | -206716.997% |
| SmileDirectClub, Inc. | 275.84 Million USD | -347.168% |
| Sector 10, Inc. | - USD | -Infinity% |
| Shandong Weigao Group Medical Polymer Company Limited | 900.72 Million USD | -36.945% |
| SheerVision, Inc. | 2.17 Million USD | -56588.952% |
| United Health Products, Inc. | -4857.00 USD | 25396435.186% |
| Vasamed, Inc. | -69.38 Thousand USD | 1777784.902% |
| Wearable Health Solutions, Inc. | 267.66 Thousand USD | -460740.684% |
| Yubo International Biotech Limited | 52.65 Thousand USD | -2342641.016% |